Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma

Lung Cancer

Volumn 92, Issue , 2016, Pages 15-18

  Caumont, Charline ^a,b   Veillon, Rémi ^a   Gros, Audrey ^a,b   Laharanne, Elodie ^a   Bégueret, Hugues ^a   Merlio, Jean Philippe ^a,b  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Adenocarcinoma; ALK; Crizotinib; Neuroendocrine; Non small cell lung carcinoma

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; CHROMOGRANIN; CISPLATIN; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PEMETREXED; SYNAPTOPHYSIN; VASCULOTROPIN RECEPTOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CANCER ADJUVANT THERAPY; CANCER GROWTH; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MIDDLE AGED; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TREATMENT RESPONSE; ADENOCARCINOMA; CLAVICLE; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; METABOLISM; NEUROENDOCRINE TUMOR; PATHOLOGY;

ADENOCARCINOMA; CLAVICLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEUROENDOCRINE TUMORS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84978646607     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.12.001     Document Type: Article

References (12)

1. [1] Soda, M., Choi, Y.L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S., Watanabe, H., Kurashina, K., Hatanaka, H., Bando, M., Ohno, S., Ishikawa, Y., Aburatani, H., Niki, T., Sohara, Y., Sugiyama, Y., Mano, H., Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448 (2007), 561–566.
2. [2] Kwak, E.L., Bang, Y.J., Camidge, D.R., Shaw, A.T., Solomon, B., Maki, R.G., Ou, S.H., Dezube, B.J., Jänne, P.A., Costa, D.B., Varella-Garcia, M., Kim, W.H., Lynch, T.J., Fidias, P., Stubbs, H., Engelman, J.A., Sequist, L.V., Tan, W., Gandhi, L., Mino-Kenudson, M., Wei, G.C., Shreeve, S.M., Ratain, M.J., Settleman, J., Christensen, J.G., Haber, D.A., Wilner, K., Salgia, R., Shapiro, G.I., Clark, J.W., Iafrate, A.J., Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363 (2010), 1693–1703.
3. [3] Takeuchi, K., Soda, M., Togashi, Y., Suzuki, R., Sakata, S., Hatano, S., Asaka, R., Hamanaka, W., Ninomiya, H., Uehara, H., Lim Choi, Y., Satoh, Y., Okumura, S., Nakagawa, K., Mano, H., Ishikawa, Y., RET ROS1 and ALK fusions in lung cancer. Nat. Med. 18 (2012), 378–381.
4. [4] WHO classification of tumours of the lung, pleura, thymus and heart. Travis, W.D., Brambilla, E., Burke, A.P., Marx, A., Nicholson, A.G., (eds.) World Health Organization Classification of Tumours, 2015, IARC Press, Lyon.
5. [5] Cabillic, F., Gros, A., Dugay, F., Begueret, H., Mesturoux, L., Chiforeanu, D.C., Dufrenot, L., Jauffret, V., Dachary, D., Corre, R., Lespagnol, A., Soler, G., Dagher, J., Catros, V., Le Calve, M., Merlio, J.P., Belaud-Rotureau, M.A., FISH Parallel and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J. Thorac. Oncol. 9:March (3) (2014), 295–306.
6. [6] Katayama, R., Shaw, A.T., Khan, T.M., Mino-Kenudson, M., Solomon, B.J., Halmos, B., Jessop, N.A., Wain, J.C., Yeo, A.T., Benes, C., Drew, L., Saeh, J.C., Crosby, K., Sequist, L.V., Iafrate, A.J., Engelman, J.A., Mechanisms of Acquired crizotinib resistance in ALK rearranged lung cancers. Sci. Transl. Med., 4, 2012, 120ra17.
7. [7] Kobayashi, Y., Sakao, Y., Ito, S., Park, J., Kuroda, H., Sakakura, N., Usami, N., Mitsudomi, T., Yatabe, Y., Transformation to sarcomatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to Crizotinib and received subsequent chemotherapies. J. Thorac. Oncol. 8 (2013), e75–e78.
8. [8] Rossing, H.H., Grauslund, M., Urbanska, E.M., Melchior, L.C., Rask, C.K., Costa, J.C., Skov, B.G., Sørensen, J.B., Santoni-Rugiu, E., Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report. BMC Res Notes., 26(6), 2013, 489.
9. [9] Popat, S., Wotherspoon, A., Nutting, C.M., Gonzalez, D., Nicholson, A.G., O′Brien, M., Transformation to high grade neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma. Lung Cancer 80 (2013), 1–4.
10. [10] Norkowski, E., Ghigna, M.R., Lacroix, L., LeChevalier, T., Fadel, É., Dartevelle, P., Dorfmuller, P., ThomasdeMontpréville, V., Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology. J. Thorac. Oncol. 8:10 (2013), 1265–1271.
11. [11] Nakamura, H., Tsuta, K., Yoshida, A., Shibata, T., Wakai, S., Asamura, H., Furuta, K., Tsuda, H., Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma. J. Clin. Pathol. 66 (2013), 705–707.
12. [12] Omachi, N., Shimizu, S., Kawaguchi, T., Tezuka, K., Kanazu, M., Tamiya, A., Asami, K., Okishio, K., Kitaichi, M., Atagi, S., A case of large-cell neuroendocrine carcinoma harboring an EML4–ALK Rearrangement with resistance to the ALK inhibitor crizotinib. J. Thorac. Oncol. 9 (2014), 40–42.